Emergence and Persistence of Letermovir-Resistant Cytomegalovirus in a Patient With Primary Immunodeficiency

BACKGROUND: Letermovir is a novel cytomegalovirus antiviral that is approved for prophylaxis in hematopoietic stem cell transplantation recipients METHODS: After obtaining informed consent, letermovir prophylaxis was started in a patient with a presumed late-onset primary, combined T- and B-cell imm...

Descripción completa

Detalles Bibliográficos
Autores principales: Popping, Stephanie, Dalm, Virgil A S H, Lübke, Nadine, Cristanziano, Veronica di, Kaiser, Rolf, Boucher, Charles A B, Van Kampen, Jeroen J A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6763208/
https://www.ncbi.nlm.nih.gov/pubmed/31660414
http://dx.doi.org/10.1093/ofid/ofz375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6763208/
https://www.ncbi.nlm.nih.gov/pubmed/31660414
http://dx.doi.org/10.1093/ofid/ofz375

Ejemplares similares